8.74
Corbus Pharmaceuticals Holdings Inc stock is traded at $8.74, with a volume of 2.41M.
It is up +5.94% in the last 24 hours and up +10.49% over the past month.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$8.25
Open:
$8.22
24h Volume:
2.41M
Relative Volume:
5.28
Market Cap:
$161.93M
Revenue:
$1.54M
Net Income/Loss:
$-84.53M
P/E Ratio:
-1.5031
EPS:
-5.8145
Net Cash Flow:
$-73.65M
1W Performance:
+5.81%
1M Performance:
+10.49%
6M Performance:
+4.92%
1Y Performance:
+8.98%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.74 | 152.85M | 1.54M | -84.53M | -73.65M | -5.8145 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Price to sales forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. – BOATS:CRBP - TradingView
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRBP Maintained by Mizuho -- Price Target Lowered to $34 - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $34 - Moomoo
Corbus Pharmaceuticals Holdings Inc (CRBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
(CRBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc (CRBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corbus Pharmaceuticals Holdings Inc - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRBP News | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
Corbus Pharmaceuticals Sharesanalyst consensus snapshot - Ad-hoc-news.de
Corbus Pharmaceuticals Holdings Inc (CRBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Institutional Confidence - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $52 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating - marketscreener.com
Oppenheimer cuts Corbus Pharmaceuticals stock price target to $52 By Investing.com - Investing.com Nigeria
Oppenheimer cuts Corbus Pharmaceuticals stock price target to $52 - Investing.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Stock (US21833E1038): Nasdaq price action in focus on a quiet news day - Ad-hoc-news.de
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals (CRBP) director sells 2,026 shares under 10b5-1 plan - Stock Titan
Corbus (NASDAQ: CRBP) director sells 2,412 shares under 10b5-1 plan - Stock Titan
Corbus (CRBP) director Jenkins sells 4,800 shares in Rule 10b5-1 trade - Stock Titan
Corbus Pharmaceuticals teases cancer, obesity data as key clinical readouts near - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals targets HPV-linked head and neck cancer with CRB-701 study - MSN
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near - Yahoo Finance
Liquidity Mapping Around (CRBP) Price Events - Stock Traders Daily
Insider Spends US$101k Buying More Shares In Corbus Pharmaceuticals Holdings - simplywall.st
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP: Lead oncology and obesity assets advance with pivotal data and strong financial runway - TradingView
CRBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Corbus Pharmaceuticals CBO Nishant Saxena buys $101,218 in stock By Investing.com - Investing.com Australia
Corbus Pharmaceuticals CBO Nishant Saxena buys $101,218 in stock - Investing.com
Insider Purchase: Chief Business Officer of $CRBP Buys 9,000 Shares - Moomoo
Corbus (CRBP) Chief Business Officer buys 13,500 shares in open market - Stock Titan
Guggenheim Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
A Quick Look at Today's Ratings for Corbus Pharmaceuticals(CRBP.US), With a Forecast Between $40 to $54 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):